Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18862468 | 0.86 | TSHR (0.68) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL25848742 | 0.84 | TSHR (0.65) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL28752749 | 0.83 | TSHR (0.64) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL23113013 | 0.77 | TSHR (0.57) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL14721723 | 0.75 | TSHR (0.51) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL4070446 | 0.74 | LMNA (0.55) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL1037880 | 0.73 | SLC40A1 (0.54) | ALDH1A1MAPK1LMNAGAAKMT2A | |
| SCHEMBL289059 | 0.73 | LMNA (0.54) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL420412 | 0.73 | LMNA (0.54) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL6427335 | 0.72 | LMNA (0.54) | TSHRL3MBTL1ALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793990-B1 | ANTIBACTERIAL COMPOUNDS | INFEX THERAPEUTICS LTD (GB) | 2023-07-19 | — | — | EP | disclosed |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-12-19 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | UTI LIMITED PARTNERSHIP (CA) | 2015-06-11 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2007084435-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | TSHR 3326/4885L3MBTL1 3622/4885ALDH1A1 722/4885 |
| US-20230060011-A1 | ANTIBACTERIAL COMPOUNDS | GAA, MGAM, NQO1 | TSHR 4699/4885L3MBTL1 3332/4885ALDH1A1 291/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | TSHR 4324/4885L3MBTL1 2809/4885ALDH1A1 591/4885 |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | TSHR 3326/4885L3MBTL1 3622/4885ALDH1A1 722/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | TSHR 4161/4885L3MBTL1 3501/4885ALDH1A1 1497/4885 |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | STAT3, STAT5A, STAT6 | TSHR 3326/4885L3MBTL1 3622/4885ALDH1A1 722/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | TSHR 4161/4885L3MBTL1 3501/4885ALDH1A1 1497/4885 |
| US-20150158894-A1 | SALICYCLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, JAK2 | TSHR 3129/4885L3MBTL1 3909/4885ALDH1A1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.